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Abstract
Background: Traumatic brain injury (TBI) is a major cause of death and disability. In this study a new method to
measure cell free DNA (CFD) for the management of TBI is tested. Our hypothesis was that CFD concentrations
correlate to the magnitude of brain damage, and may predict the outcome of injured patients.
Methods: Twenty eight patients with isolated head injury were enrolled. Their demographic and clinical data were
recorded. CFD levels were determined in patients' sera samples by a direct fluorescence method developed in our
laboratory.
Results: Mean admission CFD values were lower in patients with mild TBI compared to severe injury (760±340 ng/ml
vs. 1600 ± 2100 ng/ml, p = 0.03), and in patients with complete recovery upon discharge compared to patients
with disabilities (680 ± 260 ng/ml vs. 2000± 2300 ng/ml, p= 0.003). Patients with high CFD values had a relative
risk to require surgery of 1.5 (95% CI 0.83 to 2.9) a relative risk to have impaired outcome on discharge of 2.8
(95% CI 0.75 – 10), and a longer length of stay (12±13 days vs. 3.4±4.8 days, p=0.02). CFD values did not correlate
with CT scan based grading.
Conclusions: CFD levels may be used as a marker to assess the severity of TBI and to predict the prognosis. Its use
should be considered as an additional tool along with currently used methods or as a surrogate for them in limited
resources environment.
Keywords: Cell free DNA, Circulating DNA, Brain injury, Head trauma
Background
Traumatic brain injury (TBI) remains a major cause of
death and disability. TBI is presented as a heterogeneous
array of pathologies and severities [1]. This creates a sig-
nificant challenge to the health providers, who take care
of head injured patients, when attempting to identify
and classify the patients that may benefit from a certain
management. Currently, the basic classification of TBI
patients is based on neurological injury severity criteria
with the Glasgow Coma Scale (GCS) being the most
commonly used scale for prognostic and follow-up eval-
uations, and to enroll patients into clinical trials [2-5]. In
recent years, the traditional link between GCS and out-
come has been questioned, and published data suggest
that the predictive value of GCS should be reconsidered
[6]. The Marshall [7] and the Rotterdam [8] scores for
CT findings are the best known classification systems
based on pathoanatomic features of the injury. Despite
becoming widely used and serving as pragmatic tools,
the CT-based classifications are not free of limitations
[9]. To overcome the inherited drawbacks of the afore-
mentioned clinical and pathoanatomic methods the role
of biomarkers has been studied with S100, neuron-
specific enolase, and Hsp 70 being among the most
widely investigated [10-12]. However, failure to demon-
strate adequate sensitivity and specificity prevented their
routine clinical use as diagnostic or prognostic tools.
Accumulative data favored the potential use of circu-
lating cell-free DNA (CFD) in the plasma or serum for
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tions such as infection, inflammation, trauma, in critically
ill patients with respiratory insufficiency or pulmonary
embolism, in patients with autoimmune diseases, sepsis
and cancer [13-19]. Pioneering studies explored the poten-
tial role of CFD as a surrogate biomarker in the manage-
ment of TBI. Campello et al. demonstrated that severe
TBI is associated with elevated CFD and that persistent in-
creased concentrations of CFD correlate with mortality
[20]. Macher et al. also showed that severe TBI is associ-
ated with augmented CFD levels, and suggested that early
(within 24 hours) CFD concentrations decrease predicts a
better outcome [21]. Despite these initial promising results
on the value of CFD measurement in TBI patients this
scheme has not yet entered into clinical use. A major obs-
tacle is the applicability of the methods used to measure
CFD. The currently available research methods for CFD
measurement are work-intensive and expensive, requiring
DNA extraction and real-time polymerase chain reaction
amplification with specific primers. We recently developed
a convenient DNA assay applied directly to biologic
samples. This assay uses the fluorochrome SYBR Gold
(Invitrogen, Paisley, Scotland), which does not require
prior processing of samples. The assay is simply per-
formed by adding diluted fluorochrome to the samples
and measurement of fluorescence. The assay was proved
to be accurate, sensitive, reproducible, cheap and rapid
[22]. In a previous study, researchers from our institution
found that CFD levels correlated with brain damage and
with the neurological outcome after TBI in a rat model
[23]. The aim of the present study was to evaluate this
method for the identification of CFD in TBI patients, and
whether it may serve as an additional diagnostic and
prognostic tool capable to assist in the management of
head injured patients. We hypothesized that CFD con-
centrations would associate with severity of injury, and
that low or high levels could differentiate between good
or bad outcome, respectively.
Methods
Setup
This is an observational prospective study that took place
at the Soroka University Medical Center which is a tertiary
care referral center and a level I trauma center in southern
Israel. Patients sustaining brain injury are managed accord-
ing to the Brain Trauma Foundation Guidelines [24].
Study ethics
The research protocol was approved by the local Institu-
tional Review Board of the hospital.
Study population
Six hundred forty one patients sustaining head trauma
were admitted to our hospital during the 1 year study
period. Of this population 34 patients sustained blunt
isolated head injury. Following the exclusion criteria, 28
patients were finally enrolled into the study.
Exclusion criteria
Patients who demonstrated any other extra cranial injury
with an Abbreviated Injury Score (AIS) over 1 were ex-
cluded from the study. Other exclusion criteria included
age less than 18 years, pregnancy, malignancy, previous
brain pathology, and admission later than 4 hours after
the injury.
Data collected
Patients' demographic, injury, clinical (including neuro-
logical and neuroimaging data), and treatment characteris-
tics were collected. Specifically, we recorded the patients'
age, gender, previous medical history, type (blunt or pene-
trating) and mechanism of injury, time from injury to blood
sample withdraw, hypotension (admission systolic blood
pressure <90 mmHg), list of injuries and Injury Severity
Score (ISS), calculated probability of survival [the revised
probability of survival (RPS) is a calculated percentage
that is a prediction of the patient’s chance of surviving
t h et r a u m ab a s e do nt h ea g eo ft h ep a t i e n t ,t h eI S S ,a n dt h e
revised trauma score (RTS); it is automatically derived from
o u rt r a u m ar e g i s t r ys o f t w a r e —Israeli Trauma Registry, ITR,
version 2.2.2.14], admission GCS, a researcher blinded to
the CFD results rated the admission brain CT scans ac-
cording to the Marshall grading scale and to the Abbre-
viated Injury Scale (AIS), neurosurgical interventions
(including intracranial pressure monitoring device place-
ment, craniotomy for hematoma evacuation and decom-
pressive craniectomy), length of stay in the intensive care
unit and total hospitalization time, time on ventilator, use
of vasopressors and inotropic medications, secondary com-
plications: acute lung injury, systemic inflammatory re-
sponse syndrome (SIRS) and sepsis, outcome measures
included survival, discharge destination, and Glasgow Out-
come Score (GOS) at hospital discharge. The Glasgow
Outcome Score provides an objective assessment of the re-
covery of brain damaged patients in five categories ranging
from minor neurological deficit to death [25]. Patient blood
samples were obtained upon admission to the emergency
department during the initial evaluation of the patients,
and prior to any neurosurgical intervention took place.
CFD levels were quantified by the fluorochrome SYBR®
Gold assay which can be applied directly on biological
fluids and was previously described to be in good correl-
ation with the gold standard assay QPCR [22]. The treating
teams were blinded to the results of the CFD assays.
Statistical analysis
The mean CFD concentration of the TBI patients was
compared to that of 30 healthy volunteers whose gender
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study cohort. Statistical analysis was performed with
GraphPad Prism software (version 5.01; San Diego, CA).
Statistically significant differences between 2 groups
were tested by using the t test or the nonparametric
Mann–Whitney test. Results are presented as mean± SD.
Categorical variables were analyzed by the Fisher's exact
test. Significance was considered with p≤0.05.
Results
Participant characteristics
A total of 28 patients were enrolled in the study. There
were 23 (82%) males and 5 (18%) females. The median
age of patients was 49 (range 18–91). All patients sustained
blunt trauma. Table 1 shows patients demographic and
clinical characteristics.
The CFD concentrations of the patients were signifi-
cantly higher than those found in the control group as
demonstrated in Figure 1 (1200 ±1600 ng/ml vs. 340 ±
230 ng/ml, p =0.0001).
Mortality
There were 3 patients (11%) who died in this series.
These patients had severe head injury with low GCS
(3,7,3), low RPS (27.5%, 44.7%, 20%), and extremely high
CFD values (1925 ng/ml, 2203 ng/ml, 8787 ng/ml). The
mean CFD concentration of the dead patients was sig-
nificantly higher than that of the survivors (4305 ±
3884 ng/ml vs. 829 ±404.9 ng/ml, p= 0.006).
Clinical-anatomical grading
Comparison of the 14 patients with GCS of 14 or 15 with
the 14 patients with GCS 13 – 3 demonstrated that the
mean CFD concentration in the mild TBI group was
significantly lower than in the group of severe TBI; 760±
340 ng/ml vs. 1600±2100 ng/ml, respectively (p= 0.03).
We applied two CT scan based pathoanatomic classifi-
cation schemes. We found no significant difference be-
tween the mean CFD concentrations of patients with
Marshall 1 compared to Marshall ≥ 2, 1200±750 ng/ml
vs. 2200±1000 ng/ml, p=0.53. There was also no dif-
ference of mean CFD levels between the AIS group of
0 – 2a n dA I S≥3, 400± 1900 ng/ml vs. 750± 2500 ng/ml,
p =0.40.
Outcomes
The GOS was used as the main outcome measure. The
mean CFD concentrations were significantly higher in
the group of GOS≤ 4, 2000 ±2300 ng/ml vs. 680 ±
260 ng/ml in the group of GOS 5, p= 0.003 (Figure 2).
To determine the upper CFD cutoff levels, we per-
formed a receiver operating characteristic curve (ROC,
Figure 3) analysis and found an area under the curve of
0.872 (95% CI0.784- 0.961). The maximal likelihood
ratio (2.21) for sensitivities of 90% was 700 ng/ml, and
this value was chosen as the upper CFD cutoff. Using
the cut-off level of CFD 700 ng/ml the relative risk to
Table 1 Patients` demographics and clinical
characteristics
Age, year
Median (range) 49 (18-91)
Gender, n
Male/female, n 23/5
Initial
+GCS, n
≥14/≤13 14/14
Head
*AIS, n
0-2/3-5 10/18
Types of cranial injury, n
○ Epidural hematoma and/or Subdural hematoma 13
○ Subarachnoid hemorrhage 10
○ Intracerebral hemorrhage 5
○ Diffuse axonal injury 2
Craniotomies, n 8
¤LOS in
∞ICU, day
Median (range) 1 (0-45)
In-hospital LOS, day
Median (range) 4 (1-45)
^GOS at discharge from hospital, n (%)
Dead 3 (11)
Vegetative state 0 (0)
Severely disabled 2 (7)
Moderately disabled 6 (21)
Good recovery 17 (61)
The table shows demographic and clinical characteristics of the patients
enrolled in the study (
+GCS = Glasgow coma score;
*AIS = Abbreviated injury
score;
¤LOS = Length of stay;
∞ICU = Intensive care unit;
^GOS = Glasgow
coma score).
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Figure 1 CFD concentrations were determined in the sera of
TBI patients and compared to CFD concentrations of healthy
subjects. The mean level of the TBI group was significantly higher
than that of the control group (p=0.0001).
Shaked et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2014, 22:21 Page 3 of 6
http://www.sjtrem.com/content/22/1/21have a GOS <5 on discharge from hospital was 2.8 (95%
CI 0.75 - 10) when the CFD concentrations were high.
Using the same cut-off point, a relative risk of 1.5
(95% CI 0.83 - 2.9) for surgical procedure was found
with high CFD concentrations.
The in-hospital length of stay was significantly longer
for patients with CFD >700 ng/ml, 12 ±13 days vs. 3.4 ±
4.8 days when CFD <700 ng/ml, p=0.02.
The power of CFD was analyzed to predict good re-
covery (GOS =5) or an outcome with significant degree
of disability (GOS <5). The sensitivity and specificity
were found to be 82% (9/11) and 59% (10/17), respect-
ively, when the cut-off value of CFD was 700 ng/ml. In
comparison, the sensitivity and specificity in this study
for GCS above or below 14 as a measure to have an out-
come of GOS 5 or GOS <5 was 73% (8/11) and 65%
(11/17), respectively. The negative and positive predictive
values of CFD values alone were 83% (10/12) and 56%
(9/16), respectively. In comparison, these proportions for
GCS were 79% (11/14) and 57% (8/14), respectively.
However, when we did the analysis by using CFD <
700 ng/ml and GCS≥14 compared with CFD>700 ng/ml
and GCS≤ 13 it was found that the sensitivity of the
combined positive parameters when having GOS <5
was 100% (6/6), and the negative predictive value of the
combined negative parameters to predict GOS 5 was
100% (8/8). A specificity of 67% (8/12) of the combined
parameters was higher than each of them alone, and so
also for a positive predictive value of 60% (6/10). Inter-
estingly, in the subgroup of patients with combined
negative parameters and GOS 5 upon discharge none
of the patients required surgical intervention to evacu-
ate a cranial hematoma.
Discussion
The main results of this study show that CFD levels are
elevated in TBI patients with GCS ≤ 13, and in patients
with worse outcome as reflected by mortality, poor
GOS, prolonged length of stay in the hospital, and with
increased risk to require a surgical intervention.
All patients included in this study suffered isolated
TBI. This is in contrast with previous studies that inves-
tigated the significance of CFD in the management of
TBI in which most of the enrolled patients suffered asso-
ciated extra cranial injuries [20,21]. Plasma DNA con-
centrations increase early after injury and are higher in
patients with severe injuries and in those who develop
organ failure. Increased plasma DNA persists for days
after injuries, especially in patients with multiple organ
dysfunction syndrome [14,26]. Therefore, we excluded in
the present study any significant extra cranial injuries in
order to enable a better understanding of the impact of
brain injury on CFD. We assume that CFD levels mea-
sured early after isolated TBI reflect only the brain tissue
damage.
In our series 3 (11%) patients died. All the three pa-
tients that succumbed demonstrated remarkably high
CFD values. This finding is in agreement with other re-
ports that suggested that high persistent CFD levels may
predict fatal outcome [14,20,21,27]. The relatively small
number of dead led us to use the GOS which includes
mortality as our main outcome measure. GOS actually
reflects the combined severity of injury and the quality
of care given to the patients. Since all the patients in this
study were treated in a single center using standard pro-
tocols the GOS can be used as a reliable end point
measure. The mean CFD values of patients with GOS 5
(good recovery) were significantly lower compared with
the other grades of GOS, and high values (in this study
700 ng/ml was determined as the cut-off point) repre-
sented a 2.8 relative risk for incomplete recovery.
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Figure 2 The main outcome parameter was GOS. The mean CFD
concentration in the full recovery group (GOS 5) was significantly
lower than that of the less favorable outcome group (GOS 1–4),
p=0.003.
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Figure 3 Receiver operating characteristic curve analysis of
CFD concentrations of TBI patient group compared with
control group. Calculated area under the curve=0.872
(95% CI 0.784- 0.961).
Shaked et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2014, 22:21 Page 4 of 6
http://www.sjtrem.com/content/22/1/21To date, most clinicians base their prognostication and
initial decision making process on the neurologic injury
severity criteria defined by the GCS and on the CT scan
appearance of the brain injury. In this study we showed
that the mean value of admission CFD concentrations in
mild head injury (GCS >13) was significantly lower than
that of moderate and severe TBI. Albeit its time-
acknowledged role in the management of head injured
patients there are many reported limitations with the
use of this scale [28-31]. Our findings show that combin-
ing the CFD concentrations to the GCS results in a dra-
matic improvement of the prognostication. The negative
predictive value of low CFD values plus GCS scores >13
for good outcome (GOS 5) was 100%, and the sensitivity
of positive combined results was 100%. These findings
may be of utmost importance in the decision making
process of emergency medicine providers working in
austere environments lacking modern imaging modal-
ities; This highly sensitive combination of tests can pre-
dict accurately a good outcome of patients probably
without a need for surgical intervention. Our "mix and
measure" technique requires equipment that can be op-
erated by any hospital that has a chemistry laboratory.
The cost per one test is less than $1. In the future it is
possible to manufacture a small point-of-care measuring
device.
It has been more than 3 decades since the CT scan has
been introduced as the mainstay evaluation tool of neu-
rotrauma patients [32]. Despite the usefulness of CT
brain scan in clinical practice there is still uncertainty re-
garding the ability of CT based classification methods to
predict outcome [33]. In the present study we used AIS
and Marshall Classification to classify the findings in CT
scans. There was no significant difference between CFD
values of mild and severe grades of injury as determined
by these schemes. Our explanation to this discrepancy is
that CFD levels may better reflect the secondary damage
to brain tissue than the CT scan. Primary injury refers to
the immediate parenchymal damage occurring at the
time of injury, while secondary damage refers to poten-
tially avoidable damage that occurs at some time point
after the primary insult. The second injury is caused by
accompanying conditions to the trauma such as hypoxia,
shock, hypercarbia, hyponatremia, seizures, high tem-
perature, and brain edema of tissue surrounding the
primary lesion. This conditions lead to physiologic de-
rangements of brain parenchyma and to inevitable pro-
gressive cell damage. Another possible explanation is
that even today the CT fails to accurately evaluate the
magnitude of damage inflicted to the brain by diffuse
axonal injury without mass lesion; however, massive cell
death in this situation would result in high levels of
CFD. On the other hand, a word of caution about how
CFD (as well as other biomarkers) reflects the grade of
injury severity should be made. Biomarkers may not be
able to differentiate between a mild injury to a large vol-
ume of brain tissue from a severe injury involving a
small area, or between two similar pathologies that are
located in different parts of the brain in a way that may
greatly affect the outcome. This concern was raised by
an expert panel assembled by the National Institute of
Neurological Disorders and Stroke in 2007 [34].
Limitations of the study include: A relatively small co-
hort of patients; the inability to compare our results to
other studies since we use a different method to measure
CFD concentrations; we did not look into the possible
effect of prehospital interventions on CFD levels; the ap-
plicability to clinical situations in which patients sustain
multiple injuries.
Conclusions
The results of this study add to previous reports
about the promising role of biomarkers and particu-
larly CFD in the evaluation of TBI patients. CFD can
increase the accuracy of existing tools such as GCS
and imaging technology to differentiate mild TBI
from more severe injuries. The technique we developed
in our laboratory to determine CFD concentrations is
simple, rapid, and non-expensive. Thus, it seems to
be potentially appealing to apply in austere conditions
where rapid transfer of patients to higher levels of
care is considered.
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